Patient characteristics
| Features . | MHC class I . | MHC class II . | ||||
|---|---|---|---|---|---|---|
| Positive (n = 36) . | Negative (n = 49) . | P . | Positive (n = 54) . | Negative (n = 31) . | P . | |
| Age, median (range), y | 55 (15-79) | 34 (15-88) | .10 | 54 (15-88) | 44 (17-83) | .33 |
| Sex (male/female) | 28/8 | 32/17 | .24 | 41/13 | 19/12 | .22 |
| Sampling (1st diagnosis/relapse) | 32/4 | 48/1 | .16 | 49/5 | 31/0 | .15 |
| Histology (NS/MC/others) | 12/18/6 | 24/21/4 | .35* | 17/28/9 | 19/11/1 | .036* |
| EBV (positive/negative) | 17/11 | 12/18 | .19 | 23/17 | 6/12 | .16 |
| Performance status (0-1/2+) | 34/2 | 49/0 | .18 | 52/2 | 31/0 | .53 |
| Ann Arbor stage (I or II/III or IV) | 17/19 | 22/27 | >.99 | 25/29 | 14/17 | >.99 |
| B symptom (yes/no) | 8/28 | 17/32 | .24 | 17/37 | 8/23 | .63 |
| LDH, median (range), U/L | 204 (68-333) | 235 (143-554) | <.01 | 208 (68-441) | 227.5 (134-554) | .093 |
| MHC class I (positive/negative) | — | — | — | 27/27 | 9/22 | .071 |
| MHC class II (positive/negative) | 27/9 | 27/22 | .071 | — | — | — |
| CD4, median (range) | 428.2 (81.4-1137.6) | 425 (75-925) | .97 | 496.9 (137.6-1137.6) | 268.8 (75-700) | <.01 |
| CD8, median (range) | 284.4 (125-412.6) | 118.8 (6.2-437.4) | <.01 | 203.1 (11-400) | 118.8 (6.2-437.4) | .053 |
| FOXP3, median (range) | 81.2 (12.4-368.6) | 100 (6.4-568.6) | .30 | 93.8 (6.4-568.6) | 100 (12.4-431.2) | .52 |
| PD-L1 (positive/negative) | 34/2 | 37/12 | .036 | 46/8 | 25/6 | .76 |
| Features . | MHC class I . | MHC class II . | ||||
|---|---|---|---|---|---|---|
| Positive (n = 36) . | Negative (n = 49) . | P . | Positive (n = 54) . | Negative (n = 31) . | P . | |
| Age, median (range), y | 55 (15-79) | 34 (15-88) | .10 | 54 (15-88) | 44 (17-83) | .33 |
| Sex (male/female) | 28/8 | 32/17 | .24 | 41/13 | 19/12 | .22 |
| Sampling (1st diagnosis/relapse) | 32/4 | 48/1 | .16 | 49/5 | 31/0 | .15 |
| Histology (NS/MC/others) | 12/18/6 | 24/21/4 | .35* | 17/28/9 | 19/11/1 | .036* |
| EBV (positive/negative) | 17/11 | 12/18 | .19 | 23/17 | 6/12 | .16 |
| Performance status (0-1/2+) | 34/2 | 49/0 | .18 | 52/2 | 31/0 | .53 |
| Ann Arbor stage (I or II/III or IV) | 17/19 | 22/27 | >.99 | 25/29 | 14/17 | >.99 |
| B symptom (yes/no) | 8/28 | 17/32 | .24 | 17/37 | 8/23 | .63 |
| LDH, median (range), U/L | 204 (68-333) | 235 (143-554) | <.01 | 208 (68-441) | 227.5 (134-554) | .093 |
| MHC class I (positive/negative) | — | — | — | 27/27 | 9/22 | .071 |
| MHC class II (positive/negative) | 27/9 | 27/22 | .071 | — | — | — |
| CD4, median (range) | 428.2 (81.4-1137.6) | 425 (75-925) | .97 | 496.9 (137.6-1137.6) | 268.8 (75-700) | <.01 |
| CD8, median (range) | 284.4 (125-412.6) | 118.8 (6.2-437.4) | <.01 | 203.1 (11-400) | 118.8 (6.2-437.4) | .053 |
| FOXP3, median (range) | 81.2 (12.4-368.6) | 100 (6.4-568.6) | .30 | 93.8 (6.4-568.6) | 100 (12.4-431.2) | .52 |
| PD-L1 (positive/negative) | 34/2 | 37/12 | .036 | 46/8 | 25/6 | .76 |
Data are the number of patients, unless stated otherwise (n = 85).
MC, mixed cellularity; NS, nodular sclerosis.
NS vs MC.